Patent · US Active

Crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

US8372988B2 · kind B2 · utility

8Cited by
2References
22Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 30, 2010
Grant dateFeb 12, 2013
Priority date—
Expiry dateDec 30, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.